Since 2002, Stellar Biotics has been at the forefront of immune support science with del-IMMUNE V®, the leading metabiotic and next generation of probiotics.
DECADES OF IMMUNE HEALTH SUPPORT
Leading microbiologist, Dr. Liubov Sichel, founded Stellar Biotics LLC (formerly Pure Research Products, LLC) in 2002, for the research and development of immune-oriented nutraceutical supplements for humans and pets.
Using unique probiotic cultures, Advanced Cell Fragment Technology™ and phytonutrients as prebiotics, Dr. Sichel created supplements that work via immune cell receptors to help regulate the immune response. These supplements, called metabiotics, are based on the latest postbiotics research and are the next generation of probiotics.
We are most-widely known as the maker of del-IMMUNE V® - the leading non-prescription cell fragment supplement backed by clinical research on the U.S. market. del-IMMUNE V® is a bioactive metabolite and cell structural substance (muramyl polypeptides and DNA motifs), derived from the cell of a selected probiotic strain,“ Lactobacillus rhamnosus DV.” Scientific studies have shown that del-IMMUNE V® components can interact with certain immune cells, including cells producing secretory immunoglobulin A (sIgA), interferons (IFNs) and other immune mediators, known to play a critical role in healthy immune system function. del-IMMUNE V® replicates the process that occurs naturally in the human body, between healthy microbiota and immune receptors. These interactions are realized in immune signal production and help the innate immune system protect the body against all kinds of pathogens and threats, including stress.We develop other products which combine del-IMMUNE V®, including our probiotic, delPRO™ PROBIOTIC, and our four pet products, which combine del-IMMUNE V® with probiotics and other ingredients, to address distinct pet health needs. We also produce Daily Throat Remedy which contains peptides from bovine colostrum to regulate the immune system. We sell solely online to our customers either directly through our online shop, Amazon, or through healthcare practitioners and providers. The full line of our immune products are made and manufactured in the United States and available to customers world-wide.
Dr. Sichel continues to collaborate on scientific and clinical research with companies and universities in the United States, Canada, Ukraine, Bulgaria, and Poland to support the development of new formulations that combine del-IMMUNE V® with other recognized and innovative therapeutics.
Authors: Shadrin O. G., Hayduchyk G. A., Sichel L
Publication: SOVREMENNAYA PEDIATRIYA
Objective. To study the effectiveness of lactic acid lactic acid bacteria Lactobacillus rhamnosus V in children with virus-induced exacerbations of bronchial asthma.
Materials and methods. Were examined 35 patients aged 3 to 16 years old with exacerbation of bronchial asthma in the background of acute respiratory infections. Twenty five children of the main group were in the complex therapy of virus induced asthma exacerbation and were treated by lysate of the Lactic acid bacteria Lactobacillus rhamnosus V ( del-IMMUNE V®) at a dose of 25 mg 1 capsule 2 times a day 30 minutes before meals for 20 days. Ten patients were in the comparison group and obtained standard therapy. General clinical, immunological, allergic and statistical studies were used.
Results. Use of Del-Immune V® in the complex treatment of children with virus-nduced exacerbation of asthma, has led to a significant decrease in the frequency and severity of bronchial obstruction syndrome, which increases the effectiveness of treatment. In the main group, there was a significant increase in the concentration of IFN-gamma and a decrease in the concentration of cysteine leukotrienes in serum, and an increase in the concentration of a saliva IgA in the dynamics of treatment compared with the children in the comparison group.
Conclusions. Observed integrated therapeutic effect of del-IMMUNE V® use, no side effects and allergic reactions, justifying the appropriateness of del-IMMUNE V® inclusion in the complex therapy of virus-induced asthma exacerbations.
Authors: L.M. Lazarenko, L.P. Babenko, М.Yu. Hryhorash, V.V. Mokrozub, O.M. Demchenko, L.M. Sichel, M.Ya. Spivak
Publication: Fiziologichnyi Zhurnal
The probiotic strains of Lactobacillus casei IMV B-7280, Bifidobacterium animalis VKL, B. animalis VKB (individually) or L. casei IMV B-7280 - B. animalis VKB - B. animalis VKL composition balanced the Th1/Th2 cytokines production at normal condition and in the cases of experimental intravaginal staphylococcosis in BALB/c mice in different periods of observation. L. casei IMV B-7280 and B. animalis VKB (individually) at normal condition increased the Th1 type cytokines interleukin (IL)-12 and interferon (IFN)-γ production. Instead, B. animalis VKL after injection into intact mice did not affect the IL-12 production but slightly increased the IFN-γ production. In the cases of experimental intravaginal staphylococcosis in mice the balancing of Th1/Th2 immune response under the influence of L. casei IMV B-7280 is due to increased production of IL-12 and IFN-γ, as well as decreased Th2 type cytokine IL-4 production. The IL-12 and IFN-γ production in staphylococcus-infected mice that received B. animalis VKL or B. animalis VKB (individu-ally) was increased, but these probiotic bacteria had no significant effect on IL-4 production. Under the influence of L. casei IMV B-7280, B. animalis VKB, B. animalis VKL (individually) in the cases of experi-mental intravaginal staphylococcosis in mice the IL-4/IFN-γ ratio was significantly decreased. The shift from Th2 to Th1 type cytokines production was also observed in staphylococcus-infected mice that received L. casei IMV B-7280 - B. animalis VKB - B. animalis VKL composition. The IL-12 and IFN-γ production was increased, instead, IL-4 production as well as IL-4/IFN-γ ratio were decreased in mice that received this probiotic composition in different periods of observation.So, L. casei IMV B-7280, B. animalis VKB and B. animalis VKL (individually) and L. casei IMV B-7280 - B. animalis VKB - B. animalis VKL compo-sition are promising to create highly effective immunobiotics with immunomodulatory effect that are able to balance Th1/Th2 type of immunity by shifting the cytokine profile with decreased the IL-4/IFN-γ ratio.Key words: lactic acid bacteria; bifidobacteria; mice; intravaginal staphylococcosis; cytokines.
Authors: Nditange Shigwedha, Penny Hiwilepo-Van Hal, Li Jia, Liubov Sichel and Shuang Zhang
Prebiotics are non‐digestible food ingredients that beneficially affect the host byselectively stimulating the growth and activity of probiotic bacteria in the colon. Alldietary prebiotics and/or dietary fiber provide the physiological and beneficial effectsand, therefore, are considered as essential nutrients. According to the Codex Alimen‐tarius and the Canadian Bureau of Nutritional Sciences, dietary fiber consists ofcarbohydrates with a degree of polymerization (DP) of three or more that naturallyoccur in foods of plant origin and that are not digested and absorbed by the smallintestine. The same definition goes well along with the term dietary prebiotics. Foodand Drug Administration (FDA)|Institute of Medicine (IOM) states that dietary fiberonly comes from plant foods and anything else is regarded as “added fiber” or “novelfiber.” Dietary fiber and/dietary prebiotics can be industrially produced for a broadrange of food applications. They can also be processed into capsules for the purpose ofmicroencapsulating probiotics. In this chapter, the most recognized physiological and/or beneficial effects of the prebiotics are clarified. New evidence on the concentrationsof the short‐chain fatty acids (SCFAs) and their metabolic relationship with better healthor disease prevention in the host is provided.
Take our Quiz, Get $5
You're 46 seconds away from finding the products that are right for you.Take the Quiz